Alterity Therapeutics Limited (ASX:ATH) CEO & Chairman, Geoffrey Kempler, discusses the company’s development pipeline and lead drug candidate PTB434 for the potential treatment of Multiple System Atrophy (MSA). To watch the video visit the website here.
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – June 4, 2019. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is participating in the Finance News Network investor event today in Sydney. The event attracts a large number of retail, high net worth and sophisticated investors. The presentation follows the company’s strong presence at the ...
Alterity Therapeutics was recently featured in The Herald Sun, helping to raise awareness about Multiple System Atrophy with Richmond Football Club and Ian “Doobs” Macindoe, the club’s former chief physiotherapist. To read the full story click on the link below.
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is today commencing an investor roadshow in the US. The meetings follow the Company’s presentation of clinical data from its Phase 1 clinical trial program for its investigative drug PBT434 at the American Academy of Neurology Annual Meeting last week. The data indicate that ...
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is today releasing interim clinical data of its Phase 1 clinical trial program for its investigative drug PBT434 at the American Academy of Neurology Annual Meeting in Philadelphia, USA. The Platform Presentation titled: A First in Human Study of PBT434, a Novel Small Molecule Inhibitor ...
Alterity Therapeutics Limited, (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) will present clinical data from its lead drug candidate PBT434 at the American Academy of Neurology Annual Meeting in Philadelphia, USA, from 5-9th May 2019. Alterity will feature prominently at the Annual Meeting with a Platform Presentation on Sunday 5thMay featuring data from the company’s ...
Alterity Therapeutics Investor Presentation 10 April 2019
Alterity Therapeutics Limited, (formerly Prana Biotechnology Limited) is meeting this week with sophisticated investors in both Singapore and Hong Kong in the first leg of a global investor roadshow.
We wish to announce the Company name change has been processed by the Australian Securities and Investment Commission and the Company has changed its name from “Prana Biotechnology Limited” to “Alterity Therapeutics Limited”.
